Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 432 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Lion With Skin Cancer Has Received Radiation Therapy In Hospital May 23, 2019 Sugar and cancer – what you need to know October 20, 2020 FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma June 25, 2020 Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Cabozantinib Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy...
